Hughes Christopher, Sturdevant Mark, Cruz Ruy, Fontes Paulo, Bond Geoff, Soltys Kyle, Sindhi Rakesh, Mazariegos George, Humar Abhinav
Division of Transplant Surgery, Thomas E. Starzl Transplantation Institute, UPMC Montefiore, Pittsburgh, Pennsylvania, USA.
Clin Transpl. 2011:177-86.
As with other programs across the country, at the University of Pittsburgh liver transplantation continues to evolve after three decades. The shortage of organs represents the biggest problem in the field, and in response there has been an increase in the number of expanded-criteria-donor transplants and other methods to expand the donor pool such as live-donor, domino, and split-liver transplants. As the program has matured, we have seen an increasing number of recipients needing re-transplantation because--unlike with kidney transplants--recurrence of disease represents a significantly greater problem than immunologic graft failure. Modern immunosuppression, especially with agents such as tacrolimus, have significantly reduced the immunologic problems associated with liver transplantation. But as survival rates have improved and patients are living longer after transplant, the problems associated with long-term immunosuppression have become increasingly important. Our program, along with others, continues to look at methods to minimize the overall amount of long-term immunosuppression to which patients are exposed.
与全国其他项目一样,匹兹堡大学的肝移植在经历了三十年的发展后仍在不断演进。器官短缺是该领域最大的问题,作为应对措施,扩大标准供体移植的数量有所增加,同时还采用了其他扩大供体库的方法,如活体供体移植、多米诺移植和劈离式肝移植。随着该项目的成熟,我们发现需要再次移植的受者数量越来越多,因为与肾移植不同,疾病复发比免疫性移植失败带来的问题要严重得多。现代免疫抑制疗法,尤其是使用他克莫司等药物,已显著减少了与肝移植相关的免疫问题。但随着生存率的提高以及患者移植后存活时间的延长,与长期免疫抑制相关的问题变得越来越重要。我们的项目与其他项目一样,仍在不断探索方法,以尽量减少患者长期暴露于免疫抑制的总量。